Harmony Biosciences Holdings logo

Harmony Biosciences HoldingsNASDAQ: HRMY

Profile

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

19 August 2020

Next earnings report:

21 February 2025

Last dividends:

N/A

Next dividends:

N/A
$1.90 B
-47%vs. 3y high
80%vs. sector
-92%vs. 3y high
25%vs. sector
-81%vs. 3y high
70%vs. sector
-71%vs. 3y high
46%vs. sector

Price

after hours | Wed, 20 Nov 2024 23:00:57 GMT
$33.27+$1.16(+3.61%)

Dividend

No data over the past 3 years
$186.04 M$198.58 M
$186.04 M$46.09 M

Analysts recommendations

Institutional Ownership

HRMY Latest News

ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
accesswire.com21 November 2024 Sentiment: -

NEW YORK, NY / ACCESSWIRE / November 21, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
accesswire.com20 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

HRMY ALERT- Levi & Korsinsky Has Commenced an Investigation on Behalf of Harmony Biosciences Holdings, Inc. Shareholders Who Lost Money
accesswire.com19 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 19, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

HRMY ALERT: Levi & Korsinsky Reminds Investors of an Investigation Involving Possible Securities Fraud Violations by Harmony Biosciences Holdings, Inc.
accesswire.com18 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Shareholders that lost money on Harmony Biosciences Holdings, Inc. (HRMY) should contact Levi & Korsinsky about Securities Fraud Investigation - HRMY
accesswire.com15 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 15, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences Holdings, Inc. Investigated by Shareholder Rights Advocates - Investors Should Contact Levi & Korsinsky Regarding Potential Securities Law Violations - HRMY
accesswire.com12 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 12, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences: sNDA Of WAKIX Brings Additional Value Inflection Points
seekingalpha.com11 November 2024 Sentiment: POSITIVE

Harmony Biosciences Holdings, Inc.'s potential expansion of WAKIX targeting patients with idiopathic hypersomnia possible with filing of sNDA expected in Q4 of 2024. Net sales of Wakix in Q3 of 2024 reached $186 million. The company surpassed $2 billion in cumulative net product revenue less than 5 years on the market, highlighting rapid growth.

An Investigation Has Commenced on Behalf of Harmony Biosciences Holdings, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your HRMY Losses
accesswire.com11 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 11, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

Harmony Biosciences Holdings, Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - HRMY
accesswire.com08 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 8, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

ATTENTION Harmony Biosciences Holdings, Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your Rights
accesswire.com06 November 2024 Sentiment: NEGATIVE

NEW YORK, NY / ACCESSWIRE / November 6, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Harmony Biosciences Holdings, Inc. ("Harmony Biosciences Holdings, Inc.") (NASDAQ:HRMY) concerning possible violations of federal securities laws. On March 28, 2023, Scorpion Capital published a report detailing a string of concerns with Harmony's narcolepsy drug, Wakix (pitolisant).

What type of business is Harmony Biosciences Holdings?

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

What sector is Harmony Biosciences Holdings in?

Harmony Biosciences Holdings is in the Healthcare sector

What industry is Harmony Biosciences Holdings in?

Harmony Biosciences Holdings is in the Biotechnology industry

What country is Harmony Biosciences Holdings from?

Harmony Biosciences Holdings is headquartered in United States

When did Harmony Biosciences Holdings go public?

Harmony Biosciences Holdings initial public offering (IPO) was on 19 August 2020

What is Harmony Biosciences Holdings website?

https://www.harmonybiosciences.com

Is Harmony Biosciences Holdings in the S&P 500?

No, Harmony Biosciences Holdings is not included in the S&P 500 index

Is Harmony Biosciences Holdings in the NASDAQ 100?

No, Harmony Biosciences Holdings is not included in the NASDAQ 100 index

Is Harmony Biosciences Holdings in the Dow Jones?

No, Harmony Biosciences Holdings is not included in the Dow Jones index

When was Harmony Biosciences Holdings the previous earnings report?

No data

When does Harmony Biosciences Holdings earnings report?

The next expected earnings date for Harmony Biosciences Holdings is 21 February 2025